Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Purchased by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC raised its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 2.6% during the fourth quarter, Holdings Channel.com reports. The firm owned 22,119 shares of the specialty pharmaceutical company’s stock after purchasing an additional 560 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Supernus Pharmaceuticals were worth $800,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in SUPN. Barclays PLC boosted its stake in shares of Supernus Pharmaceuticals by 88.3% during the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock worth $3,393,000 after acquiring an additional 51,005 shares in the last quarter. Segall Bryant & Hamill LLC purchased a new stake in shares of Supernus Pharmaceuticals during the 3rd quarter worth approximately $791,000. Geode Capital Management LLC boosted its stake in shares of Supernus Pharmaceuticals by 5.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after acquiring an additional 74,438 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Supernus Pharmaceuticals by 7.6% during the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock worth $987,000 after acquiring an additional 2,121 shares in the last quarter. Finally, Bank of Montreal Can boosted its stake in shares of Supernus Pharmaceuticals by 1,508.0% during the 2nd quarter. Bank of Montreal Can now owns 116,322 shares of the specialty pharmaceutical company’s stock worth $3,287,000 after acquiring an additional 109,088 shares in the last quarter.

Insider Buying and Selling

In related news, VP Padmanabh P. Bhatt sold 700 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total value of $27,734.00. Following the completion of the sale, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,103.38. This represents a 6.45 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Georges Gemayel sold 14,213 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.62, for a total value of $520,480.06. Following the completion of the sale, the director now owns 13,315 shares of the company’s stock, valued at approximately $487,595.30. This represents a 51.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 154,913 shares of company stock valued at $5,687,914. 9.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Cantor Fitzgerald assumed coverage on Supernus Pharmaceuticals in a research note on Monday, January 6th. They issued an “overweight” rating and a $57.00 target price on the stock. Finally, Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Supernus Pharmaceuticals Stock Down 0.4 %

Shares of Supernus Pharmaceuticals stock opened at $39.00 on Thursday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $39.69. The firm has a market cap of $2.15 billion, a PE ratio of 36.45 and a beta of 0.90. The business’s fifty day moving average is $37.04 and its two-hundred day moving average is $34.36.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The company had revenue of $175.70 million for the quarter, compared to analyst estimates of $157.35 million. During the same quarter in the prior year, the company posted ($0.29) EPS. The business’s revenue for the quarter was up 14.2% compared to the same quarter last year. Equities research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.